心房动,抗凝剂和CRC结果:全国20年研究
Arnar S Agustsson1, Sigurdis Haraldsdottir1,2, Helgi Birgisson3
1Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Thrombosis and haemostasis
|February 23, 2026
概括
口服抗凝剂 (OAC) 在结直肠癌 (CRC) 患者的使用可能会降低癌症特异性死亡率,可能是由于早期的CRC检测. 然而,心血管死亡率的增加需要仔细考虑.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 结肠直肠癌 (CRC) 是癌症死亡的主要原因,经常出现胃肠道出血 (GIB).
- 假设口服抗凝剂 (OAC) 的使用会增加GIB事件,并可能导致更早的CRC检测.
研究的目的:
- 调查之前的OAC使用是否与诊断为CRC的患者的整体或CRC特异性死亡率下降有关.
- 探索OAC在CRC患者的潜在生存益处.
主要方法:
- 来自冰岛癌症登记处的2,563名冰岛CRC患者 (2000-2019) 的回顾性队列研究.
- 从医疗记录中提取了临床数据,包括并发症 (查尔森指数).
- 使用反向概率权重来平衡OAC用户和非用户之间的基线特征.
主要成果:
- 173名患者接受OAC (主要是心房) 治疗,被诊断患有CRC.
- 在最初的5年内,OAC使用者的整体死亡率相似,但CRC特异性死亡率显著降低 (HR=0.75,p=0.046).
- OAC使用者经历了显著更高的心血管死亡率.
结论:
- 在心房患者中使用OAC可能与改善存活率有关,可能是通过早期癌症检测.
- 这些发现表明OAC在CRC中的潜在生存益处,但这必须与增加的竞争性心血管死亡率相对衡量.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Venous Thrombosis III: Interprofessional Care
400
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
400
Coronary Artery Disease IV: Preventive Measures
755
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
755
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
533
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
533
Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577


